FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2901189677> ?p ?o ?g. }

• W2901189677 endingPage "73" @default.
• W2901189677 startingPage "64" @default.
• W2901189677 abstract "Background Lipotoxicity leading to excessive caspase-mediated apoptosis and inflammation is believed to drive liver damage in NAFLD. Emricasan is a pan-caspase inhibitor that decreased serum ALT and apoptotic and inflammatory markers in subjects with chronic hepatitis. Aims To assess whether 28 days of emricasan would reduce elevated levels of serum ALT, AST, cleaved cytokeratin-18, full-length cytokeratin-18, and caspase 3/7 in subjects with NAFLD and raised aminotransferases. Methods Double-blind, placebo-controlled, office-practice study assessed the efficacy, safety, and tolerability of emricasan in subjects with NAFLD and ALT levels ≥1.5 x ULN during screening. Subjects were randomised to emricasan 25 mg twice daily or matching placebo. Subjects with cirrhosis and other causes for raised aminotransferases were excluded. The primary endpoint was the change in ALT at day 28 in the emricasan group vs placebo. Results 38 subjects were randomised, 19 each to emricasan or placebo. Baseline disease factors were well balanced except for lower median ALT values in emricasan subjects. Three subjects randomised to placebo discontinued prior to day 28. ALT values decreased significantly in emricasan-treated subjects vs placebo at days 7 (P < 0.0001) and 28 (P = 0.02). cCK18 (day 7), flCK18 (days 7 and 28), and caspase 3/7 (day 7) were also significantly decreased in emricasan-treated subjects vs placebo. Emricasan treatment was generally safe and well tolerated. Conclusions Emricasan decreased ALT and biomarkers in subjects with NAFLD and raised aminotransferases after 28 days. These results support the further development of emricasan in patients with NAFLD. Trial registration: ClinicalTrials.gov, Identifier: NCT02077374." @default.
• W2901189677 created "2018-11-29" @default.
• W2901189677 creator A5010968373 @default.
• W2901189677 creator A5034166604 @default.
• W2901189677 creator A5037649284 @default.
• W2901189677 creator A5043581009 @default.
• W2901189677 creator A5057612666 @default.
• W2901189677 creator A5058771850 @default.
• W2901189677 creator A5084533266 @default.
• W2901189677 creator A5085994310 @default.
• W2901189677 date "2018-11-14" @default.
• W2901189677 modified "2023-10-14" @default.
• W2901189677 title "Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease" @default.
• W2901189677 cites W1056133434 @default.
• W2901189677 cites W1513095566 @default.
• W2901189677 cites W1622799587 @default.
• W2901189677 cites W1783939843 @default.
• W2901189677 cites W1984603193 @default.
• W2901189677 cites W2003066513 @default.
• W2901189677 cites W2003403665 @default.
• W2901189677 cites W2007516026 @default.
• W2901189677 cites W2034188379 @default.
• W2901189677 cites W2040177711 @default.
• W2901189677 cites W2045084840 @default.
• W2901189677 cites W2045175932 @default.
• W2901189677 cites W2054305537 @default.
• W2901189677 cites W2059379975 @default.
• W2901189677 cites W2062812115 @default.
• W2901189677 cites W2063437798 @default.
• W2901189677 cites W2063671857 @default.
• W2901189677 cites W2071841244 @default.
• W2901189677 cites W2078210389 @default.
• W2901189677 cites W2098555833 @default.
• W2901189677 cites W2129275826 @default.
• W2901189677 cites W2168898273 @default.
• W2901189677 cites W2617012806 @default.
• W2901189677 cites W2756046779 @default.
• W2901189677 doi "https://doi.org/10.1111/apt.15030" @default.
• W2901189677 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6587784" @default.
• W2901189677 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30430605" @default.
• W2901189677 hasPublicationYear "2018" @default.
• W2901189677 type Work @default.
• W2901189677 sameAs 2901189677 @default.
• W2901189677 citedByCount "73" @default.
• W2901189677 countsByYear W29011896772019 @default.
• W2901189677 countsByYear W29011896772020 @default.
• W2901189677 countsByYear W29011896772021 @default.
• W2901189677 countsByYear W29011896772022 @default.
• W2901189677 countsByYear W29011896772023 @default.
• W2901189677 crossrefType "journal-article" @default.
• W2901189677 hasAuthorship W2901189677A5010968373 @default.
• W2901189677 hasAuthorship W2901189677A5034166604 @default.
• W2901189677 hasAuthorship W2901189677A5037649284 @default.
• W2901189677 hasAuthorship W2901189677A5043581009 @default.
• W2901189677 hasAuthorship W2901189677A5057612666 @default.
• W2901189677 hasAuthorship W2901189677A5058771850 @default.
• W2901189677 hasAuthorship W2901189677A5084533266 @default.
• W2901189677 hasAuthorship W2901189677A5085994310 @default.
• W2901189677 hasBestOaLocation W29011896771 @default.
• W2901189677 hasConcept C126322002 @default.
• W2901189677 hasConcept C142724271 @default.
• W2901189677 hasConcept C197934379 @default.
• W2901189677 hasConcept C203092338 @default.
• W2901189677 hasConcept C204787440 @default.
• W2901189677 hasConcept C27081682 @default.
• W2901189677 hasConcept C2777214474 @default.
• W2901189677 hasConcept C2778375690 @default.
• W2901189677 hasConcept C2778772119 @default.
• W2901189677 hasConcept C2779134260 @default.
• W2901189677 hasConcept C535046627 @default.
• W2901189677 hasConcept C71924100 @default.
• W2901189677 hasConcept C90924648 @default.
• W2901189677 hasConceptScore W2901189677C126322002 @default.
• W2901189677 hasConceptScore W2901189677C142724271 @default.
• W2901189677 hasConceptScore W2901189677C197934379 @default.
• W2901189677 hasConceptScore W2901189677C203092338 @default.
• W2901189677 hasConceptScore W2901189677C204787440 @default.
• W2901189677 hasConceptScore W2901189677C27081682 @default.
• W2901189677 hasConceptScore W2901189677C2777214474 @default.
• W2901189677 hasConceptScore W2901189677C2778375690 @default.
• W2901189677 hasConceptScore W2901189677C2778772119 @default.
• W2901189677 hasConceptScore W2901189677C2779134260 @default.
• W2901189677 hasConceptScore W2901189677C535046627 @default.
• W2901189677 hasConceptScore W2901189677C71924100 @default.
• W2901189677 hasConceptScore W2901189677C90924648 @default.
• W2901189677 hasIssue "1" @default.
• W2901189677 hasLocation W29011896771 @default.
• W2901189677 hasLocation W29011896772 @default.
• W2901189677 hasLocation W29011896773 @default.
• W2901189677 hasLocation W29011896774 @default.
• W2901189677 hasOpenAccess W2901189677 @default.
• W2901189677 hasPrimaryLocation W29011896771 @default.
• W2901189677 hasRelatedWork W1990121386 @default.
• W2901189677 hasRelatedWork W2007410119 @default.
• W2901189677 hasRelatedWork W2096599976 @default.
• W2901189677 hasRelatedWork W2372453993 @default.
• W2901189677 hasRelatedWork W2776269446 @default.
• W2901189677 hasRelatedWork W2901706913 @default.

• next